Over the past six years, Stryker has consistently reported higher organic sales growth than the medtech market, according to a Seeking Alpha report.
Based on a chart calculating the market growth of 20 companies, Stryker has reported around 2 percent to 3 percent higher organic sales growth than the market average since 2013. Here are five things to know:
1. In 2013, the medtech organic sales growth was 2.4 percent while Stryker reported 5.1 percent growth. The next year, Stryker reported 5.8 percent growth while the market reported 2.8 percent growth on average.
2. Stryker has continued to increase its organic sales growth every year since 2013, with growth hitting 7.1 percent in 2017. Through the third quarter of 2018, the company reported 6.4 percent organic sales growth in 2018 based on available data.
3. While Stryker reported 6.4 percent organic sales growth in the first three quarters, the medtech market average was around 4.1 percent. The overall medtech market has experienced some fluctuation in organic sales growth over the past five years.
4. Stryker has also increased its dividend by 11.7 percent over the past three years.
5. During the third quarter of 2018, Stryker reported Mako robot use increased 40 percent and an overall knee procedure growth of 8.4 percent. At the same time, Johnson & Johnson reported a 2 percent drop in knee sales.